Bleeding risk in patients with autosomal dominant polycystic kidney disease treated with acetylsalicylic acid: implications for prevention of preeclampsia

M. F.C. de Jong; H. M. Komdeur; M. Salih; E. Meijer; The DIPAK consortium

doi:10.1007/s40620-022-01393-y

Bleeding risk in patients with autosomal dominant polycystic kidney disease treated with acetylsalicylic acid: implications for prevention of preeclampsia

M. F.C. de Jong^*, H. M. Komdeur, M. Salih, E. Meijer, The DIPAK consortium

^*Corresponding author for this work

Internal Medicine

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	2425-2427
Number of pages	3
Journal	Journal of Nephrology
Volume	35
Issue number	9
Early online date	13 Jul 2022
DOIs	https://doi.org/10.1007/s40620-022-01393-y
Publication status	Published - Dec 2022

Bibliographical note

Funding Information:
The DIPAK Consortium is sponsored by the Dutch Kidney Foundation (Grants CP10.12 and CP15.01) and the Ministry of Economic Affairs by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public–private partnerships (TKI LSHM 15018).

Access to Document

10.1007/s40620-022-01393-y

Cite this

@article{4be21c357d704cd58f66971682f5182d,

title = "Bleeding risk in patients with autosomal dominant polycystic kidney disease treated with acetylsalicylic acid: implications for prevention of preeclampsia",

author = "{de Jong}, {M. F.C.} and Komdeur, {H. M.} and M. Salih and E. Meijer and {The DIPAK consortium} and Drenth, {Joost P.H.} and Fijter, {Johan W.} and Gansevoort, {Ron T.} and Esther Meijer and Peters, {Dorien J.M.} and Wetzels, {Jack F.} and Robert Zietse",

note = "Funding Information: The DIPAK Consortium is sponsored by the Dutch Kidney Foundation (Grants CP10.12 and CP15.01) and the Ministry of Economic Affairs by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public–private partnerships (TKI LSHM 15018). ",

year = "2022",

month = dec,

doi = "10.1007/s40620-022-01393-y",

language = "English",

volume = "35",

pages = "2425--2427",

journal = "Journal of Nephrology",

issn = "1121-8428",

publisher = "Wichtig Publishing Srl",

number = "9",

}

Bleeding risk in patients with autosomal dominant polycystic kidney disease treated with acetylsalicylic acid : implications for prevention of preeclampsia. / de Jong, M. F.C.; Komdeur, H. M.; Salih, M. et al.

In: Journal of Nephrology, Vol. 35, No. 9, 12.2022, p. 2425-2427.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Bleeding risk in patients with autosomal dominant polycystic kidney disease treated with acetylsalicylic acid

T2 - implications for prevention of preeclampsia

AU - de Jong, M. F.C.

AU - Komdeur, H. M.

AU - Salih, M.

AU - Meijer, E.

AU - The DIPAK consortium

AU - Drenth, Joost P.H.

AU - Fijter, Johan W.

AU - Gansevoort, Ron T.

AU - Meijer, Esther

AU - Peters, Dorien J.M.

AU - Wetzels, Jack F.

AU - Zietse, Robert

N1 - Funding Information: The DIPAK Consortium is sponsored by the Dutch Kidney Foundation (Grants CP10.12 and CP15.01) and the Ministry of Economic Affairs by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public–private partnerships (TKI LSHM 15018).

PY - 2022/12

Y1 - 2022/12

UR - http://www.scopus.com/inward/record.url?scp=85134290538&partnerID=8YFLogxK

U2 - 10.1007/s40620-022-01393-y

DO - 10.1007/s40620-022-01393-y

M3 - Comment/Letter to the editor

C2 - 35829910

AN - SCOPUS:85134290538

VL - 35

SP - 2425

EP - 2427

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 9

ER -

Bleeding risk in patients with autosomal dominant polycystic kidney disease treated with acetylsalicylic acid: implications for prevention of preeclampsia

Bibliographical note

Access to Document

Other files and links

Cite this